NasdaqGM · Biotechnology

CAMP4 Therapeutics (CAMP)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+121.4%

$9.92 average target

$4.48+0.02 (+0.4%)Latest market snapshot · Yahoo Finance

Market cap$281.1M

Cash$86.4M

Quarterly burn$11.0M

Pipeline assets2

Short float4.2%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 121.4% upsideTargets are estimates—not guarantees—and can change after company updates.

$9.92Average target

Wall Street consensus

Strong BuyBased on 6 analyst opinions

7ratings

Buy 7Hold 0Sell 0

Price-target range

$9.92

+121.4%

Low $6.50High $15.00

CurrentAverage

Bear case$6.50+45.1%

Base case$9.92+121.4%

Bull case$15.00+234.8%

Analyst coverage6published opinions

Bullish share100%buy recommendations

Target spread$9low-to-high dispersion

Consensus score1.31.0 is strongest

Recommendation mix

Current rating breakdown

7 tracked ratings

Company profile

About CAMP4 Therapeutics

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.